SEC Tracker
Get the app
Person · CIK 1860609

Sushil Patel

Chief Executive Officer at Replimune Group; director at Revolution Medicines

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$3.3M
Noticed on Form 144$2.3M
Bought on Form 4$0
Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Replimune Group REPLCommon StockDirectly708,151Aug 10, 2026 · Filing · EDGAR
Replimune Group REPLEmployee Stock Option (right to buy)
exercise $7.61, expires Apr 1, 2036, into Common Stock
Directly376,860Apr 1, 2026 · Filing · EDGAR
Revolution Medicines RVMDCommon StockDirectly21,656Jun 29, 2026 · Filing · EDGAR
Revolution Medicines RVMDStock Option (Right to Buy)
exercise $37.54, expires Jun 19, 2034, into Common Stock
Directly13,000Jun 29, 2026 · Filing · EDGAR

Sold and noticed by quarter

Sushil Patel: dollars sold on Form 4 and noticed on Form 144 per quarter, Q2 2022 to Q4 2026$1.2M$0Q2 2022: notice not machine-readableQ2 2022: $156K sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $556K noticed on Form 144Q2 2023: $418K sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $71K noticed on Form 144Q2 2024: $210K sold on Form 4Q3 2024: $85K noticed on Form 144Q3 2024: $95K sold on Form 4Q4 2024: $441K noticed on Form 144Q4 2024: $395K sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $202K sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $111K noticed on Form 144Q4 2025: $111K sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $1M noticed on Form 144Q2 2026: $1.2M sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $510K sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q2 2022Q2 2023Q2 2024Q2 2025Q2 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$510K—
Q2 2026$1.2M$1M
Q4 2025$111K$111K
Q2 2025$202K—
Q4 2024$395K$441K
Q3 2024$95K$85K
Q2 2024$210K$71K
Q2 2023$418K$556K
Q2 2022$156KNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 30, 2026 · 1 notice
Jun 29, 20265,580 · ~$1MJun 29, 2026Sold as noticed Sold 5,580 in 9 sales, Jun 29 to Jun 29 · $1M Form 4Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Jun 2, 2025 · 1 notice
Dec 2, 202510,000 · ~$111KDec 2, 2025Sold as noticed Sold 10,000 at $11.13 on Dec 2 · $111K Form 4Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Apr 3, 2024 · 1 notice
Dec 16, 202415,000 · ~$189KDec 16, 2024Partly sold Sold 10,000 at $12.42 on Dec 16 · $124K likely match Form 4Filing · EDGAR
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 7, 2023 · 1 notice
Oct 31, 20245,000 · ~$253KOct 31, 2024Sold as noticed Sold 5,000 at $54.14 on Oct 31 · $271K Form 4Filing · EDGAR
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 6, 2023 · 2 notices
Jul 9, 20242,155 · ~$85KJul 9, 2024Sold as noticed Sold 2,155 at $44.00 on Jul 9 · $95K Form 4Filing · EDGAR
Apr 10, 20242,155 · ~$71KApr 10, 2024Sold as noticed Sold 2,155 at $37.00 on Apr 10 · $80K Form 4Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Mar 15, 2023 · 1 notice
Jun 13, 202323,710 · ~$556KJun 13, 2023Partly sold Sold 5,698 in 2 sales, Jun 13 to Jun 13 · $137K likely match Form 4Filing · EDGAR
Sales without a matching Form 144 · 6 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Replimune Group (REPL): Sold 39,341 at $12.97 on Aug 10, 2026 · $510KFiling · EDGAR
———Sold without notice Replimune Group (REPL): Sold 37,324 at $5.08 on May 18, 2026 · $190KFiling · EDGAR
———Sold without notice Replimune Group (REPL): Sold 25,105 at $8.06 on May 20, 2025 · $202KFiling · EDGAR
———Sold without notice Replimune Group (REPL): Sold 20,194 at $6.47 on May 16, 2024 · $131KFiling · EDGAR
———Sold without notice Replimune Group (REPL): Sold 15,575 at $18.05 on May 16, 2023 · $281KFiling · EDGAR
———Notice not machine-readable Replimune Group (REPL): Sold 10,687 at $14.59 on May 16, 2022 · $156KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Replimune Group REPL Chief Executive Officer · filings 2021 to 2026 · sold $1.8M · $856K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Aug 10, 2026Open-market or private sale−39,341$12.97$510K708,151 directFiling · EDGAR
May 18, 2026Open-market or private sale−37,324$5.08$190K747,492 directFiling · EDGAR
Apr 1, 2026Grant or award from the company+251,240784,816 directFiling · EDGAR
Apr 1, 2026Grant or award from the company
Employee Stock Option (right to buy)
+376,860376,860 directFiling · EDGAR
Dec 19, 2025Grant or award from the company+200,000533,576 directFiling · EDGAR
Dec 2, 2025Sale under a 10b5-1 plan−10,000$11.13$111K333,576 directFiling · EDGAR
May 20, 2025Open-market or private sale−25,105$8.06$202K343,576 directFiling · EDGAR
Apr 1, 2025Grant or award from the company+166,667368,681 directFiling · EDGAR
Apr 1, 2025Grant or award from the company
Employee Stock Option (right to buy)
+250,000250,000 directFiling · EDGAR
Dec 16, 2024Sale under a 10b5-1 plan−10,000$12.42$124K202,014 directFiling · EDGAR
May 16, 2024Open-market or private sale−20,194$6.47$131K212,014 directFiling · EDGAR
Apr 1, 2024Grant or award from the company+83,335232,208 directFiling · EDGAR
Apr 1, 2024Grant or award from the company
Employee Stock Option (right to buy)
+250,000250,000 directFiling · EDGAR
Jun 13, 2023Sale under a 10b5-1 plan−5,145$24.11$124K149,426 directFiling · EDGAR
Jun 13, 2023Sale under a 10b5-1 plan−553$23.44$13K148,873 directFiling · EDGAR
May 16, 2023Open-market or private sale−15,575$18.05$281K154,571 directFiling · EDGAR
Apr 1, 2023Grant or award from the company+40,000170,146 directFiling · EDGAR
Apr 1, 2023Grant or award from the company
Employee Stock Option (right to buy)
+60,00060,000 directFiling · EDGAR
May 16, 2022Open-market or private sale−10,687$14.59$156K130,146 directFiling · EDGAR
Apr 1, 2022Grant or award from the company+52,500140,833 directFiling · EDGAR
Apr 1, 2022Grant or award from the company
Employee Stock Option (right to buy)
+78,75078,750 directFiling · EDGAR
May 3, 2021Grant or award from the company+88,33388,333 directFiling · EDGAR
May 3, 2021Grant or award from the company
Employee Stock Option (right to buy)
+125,000125,000 directFiling · EDGAR

Revolution Medicines RVMD Director · filings 2022 to 2026 · sold $1.5M · $1.4M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 29, 2026Option or RSU exercised or converted+2,955$37.54$111K27,236 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−300$183.17$55K26,936 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−900$184.59$166K26,036 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−1,100$185.90$204K24,936 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−858$186.92$160K24,078 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−300$187.83$56K23,778 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−100$188.57$19K23,678 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−600$190.55$114K23,078 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−541$191.87$104K22,537 directFiling · EDGAR
Jun 29, 2026Sale under a 10b5-1 plan−881$192.61$170K21,656 directFiling · EDGAR
Jun 29, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−2,95513,000 directFiling · EDGAR
Jun 18, 2026Grant or award from the company+1,19124,281 directFiling · EDGAR
Jun 18, 2026Grant or award from the company
Stock Option (Right to Buy)
+3,1273,127 directFiling · EDGAR
Jun 26, 2025Grant or award from the company+3,14223,090 directFiling · EDGAR
Jun 26, 2025Grant or award from the company
Stock Option (Right to Buy)
+11,57411,574 directFiling · EDGAR
Oct 31, 2024Option or RSU exercised or converted+5,000$24.84$124K24,948 directFiling · EDGAR
Oct 31, 2024Sale under a 10b5-1 plan−5,000$54.14$271K19,948 directFiling · EDGAR
Oct 31, 2024Option or RSU exercised or converted
Stock Option (Right to Buy)
−5,00013,400 directFiling · EDGAR
Jul 9, 2024Option or RSU exercised or converted+2,155$16.80$36K22,103 directFiling · EDGAR
Jul 9, 2024Sale under a 10b5-1 plan−2,155$44.00$95K19,948 directFiling · EDGAR
Jul 9, 2024Option or RSU exercised or converted
Stock Option (Right to Buy)
−2,15532,490 directFiling · EDGAR
Jun 20, 2024Grant or award from the company+4,24819,948 directFiling · EDGAR
Jun 20, 2024Grant or award from the company
Stock Option (Right to Buy)
+15,95515,955 directFiling · EDGAR
Apr 10, 2024Option or RSU exercised or converted+2,155$16.80$36K17,855 directFiling · EDGAR
Apr 10, 2024Sale under a 10b5-1 plan−2,155$37.00$80K15,700 directFiling · EDGAR
Apr 10, 2024Option or RSU exercised or converted
Stock Option (Right to Buy)
−2,15534,645 directFiling · EDGAR
Jun 8, 2023Grant or award from the company+5,20015,700 directFiling · EDGAR
Jun 8, 2023Grant or award from the company
Stock Option (Right to Buy)
+18,40018,400 directFiling · EDGAR
Jun 16, 2022Grant or award from the company+10,50010,500 directFiling · EDGAR
Jun 16, 2022Grant or award from the company
Stock Option (Right to Buy)
+36,80036,800 directFiling · EDGAR
All 35 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Aug 12, 2026Form 4Replimune Group REPLFiling · EDGAR
Jul 1, 2026Form 4Revolution Medicines RVMDFiling · EDGAR
Jun 29, 2026Form 144Revolution Medicines RVMDFiling · EDGAR
Jun 23, 2026Form 4Revolution Medicines RVMDFiling · EDGAR
May 20, 2026Form 4Replimune Group REPLFiling · EDGAR
Apr 7, 2026Form 4Replimune Group REPLFiling · EDGAR
Dec 19, 2025Form 4Replimune Group REPLFiling · EDGAR
Dec 4, 2025Form 4Replimune Group REPLFiling · EDGAR
Dec 2, 2025Form 144Replimune Group REPLFiling · EDGAR
Jun 30, 2025Form 4Revolution Medicines RVMDFiling · EDGAR
May 22, 2025Form 4Replimune Group REPLFiling · EDGAR
Apr 3, 2025Form 4Replimune Group REPLFiling · EDGAR
Dec 18, 2024Form 4Replimune Group REPLFiling · EDGAR
Dec 16, 2024Form 144Replimune Group REPLFiling · EDGAR
Nov 4, 2024Form 4Revolution Medicines RVMDFiling · EDGAR
Oct 31, 2024Form 144Revolution Medicines RVMDFiling · EDGAR
Jul 10, 2024Form 4Revolution Medicines RVMDFiling · EDGAR
Jul 9, 2024Form 144Revolution Medicines RVMDFiling · EDGAR
Jun 28, 2024Form 4/ARevolution Medicines RVMDFiling · EDGAR
Jun 24, 2024Form 4Revolution Medicines RVMDFiling · EDGAR
May 20, 2024Form 4Replimune Group REPLFiling · EDGAR
Apr 12, 2024Form 4Revolution Medicines RVMDFiling · EDGAR
Apr 10, 2024Form 144Revolution Medicines RVMDFiling · EDGAR
Apr 3, 2024Form 4Replimune Group REPLFiling · EDGAR
Jun 15, 2023Form 4Replimune Group REPLFiling · EDGAR
Jun 13, 2023Form 144Replimune Group REPLFiling · EDGAR
Jun 12, 2023Form 4Revolution Medicines RVMDFiling · EDGAR
May 18, 2023Form 4Replimune Group REPLFiling · EDGAR
Apr 4, 2023Form 4Replimune Group REPLFiling · EDGAR
Jun 17, 2022Form 4Revolution Medicines RVMDFiling · EDGAR
Jun 17, 2022Form 3Revolution Medicines RVMDFiling · EDGAR
May 18, 2022Form 4Replimune Group REPLFiling · EDGAR
Apr 5, 2022Form 4Replimune Group REPLFiling · EDGAR
May 5, 2021Form 4Replimune Group REPLFiling · EDGAR
May 5, 2021Form 3Replimune Group REPLFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.